VCA Animal Hospitals And Zoetis Partner On A Successful Clinical Study On New-To-Market Clavamox Chewable Antibiotic Tablets

LOS ANGELES--(BUSINESS WIRE)--VCA Animal Hospitals, the nation’s largest animal hospital chain, continues to support clinical research with their Clinical Studies program. In a recent collaboration, VCA partnered with Zoetis, the world’s leading animal health company, to conduct a clinical study that tested the palatability of Clavamox^® Chewable tablets with client-owned dogs at VCA veterinary hospitals across the U.S. The study was conducted across VCA’s national network of hospitals in accordance with a protocol approved by FDA’s Center for Veterinary Medicine for a chewable version of an incredibly important, and previously approved, veterinary antibiotic. A total of 1,567 doses were administered to 112 dogs, resulting in an 83 percent overall voluntary acceptance rate for Clavamox Chewable when offered from an empty bowl or owner’s hand.*1

“Having this important antibiotic available as a chewable form will mean it is much easier for our clients to administer this medication,” said Philip Bergman, DVM, PhD, Dipl ACVIM, VCA Director of Clinical Studies. “This clinical study is another example of a successful partnership between Zoetis and VCA, as we are both dedicated to moving veterinary medicine forward by bringing new medications to our patients and their owners.”

The VCA Clinical Studies program started four years ago and has coordinated a large number of sponsored studies with various industry partners. The program also performs non-sponsored studies with many VCA clinicians, residents and interns for the advancement of research in clinical animal care and has multiple ongoing collaborations with veterinary universities in North America and the UK. For additional information about the VCA Clinical Studies program, contact Dr. Bergman at philip.bergman@vca.com.

About Zoetis

Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of US$4.9 billion with approximately 9,000 employees. For more information, visit www.Zoetis.com.

About VCA

VCA (WOOF on NASDAQ) is a leading provider of pet health care services in the country delivered through over 800 small animal veterinary hospitals in the US and Canada, a preeminent nationwide clinical laboratory system that services all 50 states and Canada (Antech Diagnostics), the leading animal diagnostic imaging company in the market (Sound), and Camp Bow Wow (CBW), the nation’s Premier Doggy Day and Overnight Camp® franchise, an Inc. 5000 company.

VCA Animal Hospitals operates more than 800 small animal veterinary hospitals in the U.S. and Canada. The hospitals are staffed by more than 4,500 fully qualified, dedicated and compassionate veterinarians to give pets the very best in medical care, of which over 500 are board-certified specialists who are experts in areas such as Oncology, Cardiology, Emergency and Critical Care, and Surgery for animals. VCA Animal Hospitals provides a full range of general practice services to keep pets well and specialized treatments when pets are ill. For more information, please visit www.VCAhospitals.com or follow on Twitter @vcapethealth.

1 Data on file. CLAVAMOX CHEWABLE Tablets Palatability Study in Client-Owned Dogs. Study No. A163C-US-13-170, Zoetis Inc.